Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic.


OBJECTIVE
To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS.


METHODS
Vital signs and laboratory values obtained before and during the aripiprazole trial were compared.


RESULTS
Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure.


CONCLUSIONS
In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.
Dew
Rachel E
RE
Department of Psychiatry, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, USA. rdew@wfubmc.edu
Rosenquist
Peter B
PB
McCall
W Vaughn
WV
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D017058:Mexican Americans; D009459:Neuroleptic Malignant Syndrome / Q000503:physiopathology* / Q000523:psychology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole